slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
221,281-221,310 of 319,975
03
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
04
The slide uses a vertical timeline structure to organize clinical catalysts by asset.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a Gantt-style visualization to show the progress of various drug candidates across different clinical phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
08
The slide outlines a partnership structure involving three distinct therapeutic approaches and a financial deal structure.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a timeline framework to demonstrate historical traction and partnership growth.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a list-based comparison to show market potential for specific drug targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
12
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a combination of a biological mechanism diagram, a checklist of target criteria, and histological images to validate the therapeutic target.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a circular process diagram to illustrate the therapy lifecycle, followed by a zoomed-in molecular interaction diagram.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
15
Includes clinical trial screening data for specific cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
16
The slide uses a table to compare patient demographics and clinical characteristics across different cancer types, specifically focusing on the sufficiency of the melanoma cohort for further development.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
17
Slide compares two generations of therapy; includes clinical metrics like cORR and mDOR.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
19
The table highlights key clinical metrics including ORR, cORR, mDOR, and mFU for various patient subgroups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
20
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Data cut-off Sep 30, 2023. N=16 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
22
Data cut-off Sep 30, 2023. Includes extensive footnotes regarding methodology and specific patient cases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
Includes waterfall plot for BOR and spider plot for response over time. Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses a matrix structure to define the patient population and market opportunity.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
25
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
26
The slide uses a biological diagram to illustrate the synergy between CD4 and CD8 T cells in inducing tumor cell death.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses two line charts to demonstrate the superior durability of CD4 T cells in a serial killing assay.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
28
Includes specific clinical details on Grade 3/4 events for two patients in the highest dose cohort (DL4b).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
29
Data cut-off Sep 30, 2023. Slide 29.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
30
Includes waterfall plot and spider plot (longitudinal response). Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
31
Includes p-values for statistical significance across four distinct clinical metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
32
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit